CIBC Bancorp USA Inc. Takes Position in Intuitive Surgical, Inc. $ISRG

CIBC Bancorp USA Inc. acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 62,580 shares of the medical equipment provider’s stock, valued at approximately $27,988,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SteelPeak Wealth LLC lifted its holdings in Intuitive Surgical by 28.7% in the 3rd quarter. SteelPeak Wealth LLC now owns 41,993 shares of the medical equipment provider’s stock worth $18,781,000 after buying an additional 9,364 shares in the last quarter. Atlantic Union Bankshares Corp boosted its stake in Intuitive Surgical by 19.3% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 22,759 shares of the medical equipment provider’s stock valued at $10,179,000 after acquiring an additional 3,676 shares during the last quarter. World Investment Advisors grew its holdings in Intuitive Surgical by 238.3% during the 3rd quarter. World Investment Advisors now owns 5,399 shares of the medical equipment provider’s stock worth $2,415,000 after acquiring an additional 3,803 shares in the last quarter. E. Ohman J or Asset Management AB grew its holdings in Intuitive Surgical by 4.1% during the 3rd quarter. E. Ohman J or Asset Management AB now owns 28,306 shares of the medical equipment provider’s stock worth $12,659,000 after acquiring an additional 1,123 shares in the last quarter. Finally, Valley Wealth Managers Inc. increased its position in shares of Intuitive Surgical by 52.7% in the 3rd quarter. Valley Wealth Managers Inc. now owns 4,084 shares of the medical equipment provider’s stock worth $1,826,000 after purchasing an additional 1,409 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ISRG has been the subject of a number of research reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Intuitive Surgical in a report on Monday, December 29th. UBS Group dropped their price objective on shares of Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating on the stock in a report on Tuesday. Raymond James Financial raised their price target on Intuitive Surgical from $603.00 to $615.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. TD Cowen upgraded Intuitive Surgical to a “strong-buy” rating in a research report on Tuesday, January 27th. Finally, Zacks Research upgraded shares of Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $614.95.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Company fundamentals and market positioning — Intuitive reported a strong January quarter (beats on revenue and EPS, ~19% revenue growth year‑over‑year) and is pursuing lower‑cost da Vinci systems to target fast‑growing ambulatory surgery centers, which could expand procedure volume outside hospitals over time. No external link
• Neutral Sentiment: Sector and competitive news with limited direct impact — other medtech product launches and approvals in the broader ecosystem (e.g., Merit Medical’s new esophageal stent) are being reported but do not directly displace Intuitive’s robotic surgery franchise. MMSI Launches Resilience TTS Stent for Esophageal Fistulas, Strictures
• Negative Sentiment: FDA regulatory flag — Intuitive was flagged by the FDA over a medical device issue, which raises near‑term regulatory and operational risk concerns; such notices can prompt customer caution, warranty/repair costs, or increased oversight that pressure sentiment. Intuitive Surgical flagged by FDA over medical device issue
• Negative Sentiment: Analyst outlook softened — UBS cut its price target from $570 to $550 and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure; the new target still implies some upside versus current levels but reflects more cautious sentiment. Intuitive Surgical (NASDAQ:ISRG) Price Target Lowered to $550.00 at UBS Group

Insider Activity at Intuitive Surgical

In related news, SVP Patricia L. Wadors sold 220 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $499.71, for a total value of $109,936.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Myriam Curet sold 421 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $494.96, for a total transaction of $208,378.16. Following the transaction, the executive vice president directly owned 409 shares in the company, valued at $202,438.64. The trade was a 50.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 32,943 shares of company stock worth $17,279,568 over the last quarter. 0.70% of the stock is currently owned by corporate insiders.

Intuitive Surgical Trading Down 1.0%

Shares of Intuitive Surgical stock opened at $477.73 on Thursday. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $603.88. The company has a market cap of $169.66 billion, a P/E ratio of 60.55, a P/E/G ratio of 3.72 and a beta of 1.66. The stock has a 50-day moving average price of $507.10 and a 200 day moving average price of $512.85.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.27 by $0.26. The business had revenue of $2.87 billion during the quarter, compared to analyst estimates of $2.72 billion. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.Intuitive Surgical’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period last year, the company earned $2.21 earnings per share. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.